Project Grant R61CA315160
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $212K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
- The National Cancer Institute awarded The Medical University of South Carolina $643,053 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to explore the kinase-independent functions of cyclin D3 in T cells and its effects on tumor progression and immunotherapy efficacy. The research addresses T-cell poor infiltration and survival in solid tumor microenvironments by investigating how cyclin D3 regulates intracellular cholesterol homeostasis and adhesion protein expression in...
- The National Cancer Institute awarded the University of North Carolina at Chapel Hill $207,802 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop multiplexed multiscale imaging technologies for studying cellular immunotherapies. The recipient will develop new fluorescent probes to simultaneously visualize many proteins at once in immune cells, tumor cells, and at the immune synapse, with spatial resolution ranging from one micron to tens of...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...
- The National Cancer Institute awarded The Medical University of South Carolina $205,788 on September 10, 2025, under the Cancer Research Manpower program (CFDA 93.398) to conduct research on peroxisome biogenesis in anti-tumor T cell metabolic fitness. The research investigates how peroxisomes—organelles that regulate fatty acids and reactive oxygen species—influence T cell exhaustion and dysfunction within the immunosuppressive tumor microenvironment. The study is motivated by preliminary...
- The National Cancer Institute awarded Duke University $402,135 on May 1, 2026, to develop SCHICAR, a single-cell tri-modal platform that simultaneously captures high-resolution three-dimensional genome interactions (including enhancer-promoter loops), chromatin accessibility, and transcriptomes from individual cells in cancer research. Duke's work addresses a critical limitation in existing single-cell three-dimensional genome methods, which suffer from poor efficiency in capturing long-range...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...
- The National Cancer Institute awarded the University of Virginia $161,500 for cancer cell biology research on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The project develops methods to classify pancreatic ductal adenocarcinoma circulating tumor cells by single-cell deformability. Researchers will create a perfusable co-culture system with cancer-associated fibroblasts to generate pancreatic cancer cells expressing varied epithelial and mesenchymal states under shear...
- The National Cancer Institute awarded The Medical University of South Carolina $531,584 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate heat shock protein 70 (HSP70) as a therapeutic target in pancreatic ductal adenocarcinoma. The research identifies HSP70, a stress-inducible molecular chaperone markedly overexpressed in primary and metastatic pancreatic cancer, as a selective therapeutic vulnerability. The investigator team developed a...
- The National Cancer Institute awarded The Johns Hopkins University $387,178 on August 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop lipid nanoparticle-based immunotherapy strategies for in-situ generation of dual T cell receptor/chimeric antigen receptor T cells targeting cancer. The award funds research to address the barrier of scalable systems for delivering genetic material to CD4+ T cells. The project leverages a high-throughput mRNA lipid...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $693,290 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to perform whole-slide multiplex immunofluorescence tissue imaging analysis of 450 stage II/III primary invasive melanomas from the INTERMEL case-control study, focusing on immune cell and tumor vasculature markers to identify spatial tumor microenvironment signatures that distinguish aggressive from indolent disease....